IQVIA (NYSE:IQV) Sees Large Volume Increase – Should You Buy?

IQVIA Holdings Inc. (NYSE:IQV) saw an uptick in trading volume on Monday . 990,554 shares traded hands during mid-day trading, a decline of 13% from the previous session’s volume of 1,140,433 shares.The stock last traded at $191.39 and had previously closed at $192.68.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft dropped their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Jefferies Financial Group lowered shares of IQVIA from a “buy” rating to a “hold” rating and dropped their price target for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. The Goldman Sachs Group cut their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Robert W. Baird lowered their price objective on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a report on Friday, November 1st. Finally, Barclays reduced their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Up 0.2 %

The firm has a fifty day moving average price of $225.08 and a 200 day moving average price of $227.79. The firm has a market capitalization of $34.73 billion, a price-to-earnings ratio of 25.11, a P/E/G ratio of 1.98 and a beta of 1.51. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

A number of institutional investors and hedge funds have recently modified their holdings of the business. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the 3rd quarter valued at $27,000. Park Place Capital Corp acquired a new stake in IQVIA in the third quarter worth $28,000. Versant Capital Management Inc grew its position in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC bought a new position in IQVIA in the second quarter valued at approximately $27,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA in the second quarter valued at approximately $29,000. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.